The challenge, as with BCAT2, is the shadow of maple syrup urine disease—a condition where BCKDH is overly active or BCKDK is deficient, leading to continuous BCAA breakdown and dangerously low BCAA levels in the body. This evidence concerns the gene BCAT2 and maple syrup urine disease.